Bavarian Nordic

Companies Bavarian Nordic

News Bavarian Nordic

• Bavarian Nordic Initiates Pivotal Phase 3 Trial of PROSTVAC Prostate Cancer Immunotherapy

  Bavarian Nordic A/S announced that its subsidiary, BN ImmunoTherapeutics has initiated the pivotal Phase 3 trial of PROSTVAC® for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol Assessment agre more

• Bavarian Nordic's Immunotherapy Product Candidate CV-301 Shows Promise in Breast and Ovarian Cancer

  Bavarian Nordic A/S  announced that encouraging clinical trial results with CV-301 in patients with metastatic breast or ovarian cancer were published in Clinical Cancer Research. Through an expanded collaboration with the National Cancer Institute (NCI) and license with the National Institutes of H more

• Bavarian Nordic Obtains Rights to New Cancer Vaccine Product Candidates

  Bavarian Nordic A/S announced that its BN ImmunoTherapeutics subsidiary has entered into an expanded strategic partnership with the National Cancer Institute (NCI). Under the licensing and Cooperative Research and Development Agreements (CRADA), the NCI and Bavarian Nordic will jointly develop new o more

Market studies Bavarian Nordic

• Bavarian Nordic A/S (BAVA) - Financial and Strategic SWOT Analysis Review

  Bavarian Nordic A/S (Bavarian Nordic) is a publicly held bio pharmaceutical company developing and producing vaccines for the treatment and prevention of life-threatening diseases. The company primarily focuses on areas of biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and more

• Vivalis SA (VLS) - Financial and Strategic SWOT Analysis Review

  Vivalis SA (Vivalis) is a public bio-pharmaceutical company, engaged in the provision of cell based solutions for the industrial manufacture of viral vaccines and therapeutic proteins. The company also develops vaccines and drugs to prevent and cure viral diseases. Vivalis has developed two innovati more

• SIGA Technologies, Inc. (SIGA) - Financial and Strategic SWOT Analysis Review

  SIGA Technologies, Inc. (SIGA) is a publicly held company engaged in research, developing and commercializing anti-infectives for the treatment and prevention of serious infectious diseases. The product pipeline of the company includes ST-246, an orally administered antiviral drug for the treatment more

Websites Bavarian Nordic